Articles From: Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder to CorpBanca Raises More Than US$620 Million in New Capital


2013/2/20
http://media.marketwire.com/attachments/201107/29720_cornerstoneLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=987832&ProfileId=051205&sourceType=1 CARY, NC --
Sign-up for Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder investment picks
2013/3/20
http://media.marketwire.com/attachments/201205/45247_cornerstone.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=999012&ProfileId=051205&sourceType=1 CARY, NC --
Sign-up for Cornerstone Therapeutics Inc. Announces Retention of Advisors investment picks
2013/5/9
http://media.marketwire.com/attachments/201205/45247_cornerstone.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1015576&ProfileId=051205&sourceType=1 CARY, NC --
Sign-up for Cornerstone Therapeutics Reports First Quarter 2013 Financial Results investment picks
2013/2/22
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of Cornerstone Therapeutics, Inc. (“Cornerstone”) (Nasdaq: CRTX) related to a going private proposal by Chiesi Farmaceutici SpA (“Chiesi”) for shareholders.
Sign-up for Cornerstone Therapeutics Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Investigate Going Private Proposal investment picks
2013/5/2
http://media.marketwire.com/attachments/201205/45247_cornerstone.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1013304&ProfileId=051205&sourceType=1 CARY, NC --
Sign-up for Cornerstone Therapeutics to Host First Quarter 2013 Conference Call investment picks
2013/3/7
http://media.marketwire.com/attachments/201107/29720_cornerstoneLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=994396&ProfileId=051205&sourceType=1 CARY, NC --
Sign-up for Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2012 Conference Call investment picks
2013/4/24
Corning Inc.'s (GLW) first-quarter income rose 4.2% as the maker of TV-screen glass benefited from lower tax costs, though revenue declined.
Sign-up for Corning 1st-Quarter Profit Up 4.2% on Lower Tax Expenses investment picks
2013/3/5
http://media.marketwire.com/attachments/201207/48637_corning.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=992942&ProfileId=051205&sourceType=1 HICKORY, NC --
Sign-up for Corning Showcases Wireless Healthcare Solutions at HIMSS 2013 investment picks
2013/2/25
http://media.marketwire.com/attachments/201109/32654_corningmobileaccesslogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=986019&ProfileId=051205&sourceType=1 HICKORY, NC --
Sign-up for Corning to Showcase Latest Wireless Solutions at Mobile World Congress investment picks
2013/5/16
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0874473001&sourceType=1 http://media3.marketwire.com/logos/20130402-COROM.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Coro Announces Election of Directors and Alteration of Articles to Incorporate Advance Notice Provisions investment picks
2013/5/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0872305001&sourceType=1 http://media3.marketwire.com/logos/20130402-COROM.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Coro Announces Letter of Intent for Berta Project and Provides Update on Its Other Projects investment picks
2013/4/2
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0864029001&sourceType=1 http://media3.marketwire.com/logos/20130402-COROM.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Coro Provides Update on Sale of Chacay investment picks
2013/2/19
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0853917001&sourceType=1 http://www.ccnmatthews.com/logos/20070614-coro0614.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Coro to Sell Chacay Property investment picks
2013/4/24
BURLINGTON, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the departure of Dr.
Sign-up for Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr. investment picks
2013/2/25
BURLINGTON, Mass., Feb.
Sign-up for Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Psoriasis investment picks
2013/4/11
BURLINGTON, Mass., April 11, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it has sold through its at-the-market program 1,000,000 shares of its common stock to Jennison Associates LLC (on behalf of fund clients) at yesterday's closing price of $10.12. MLV & Co., located in New York City, acted as the sales agent for the sale.
Sign-up for Coronado Biosciences Announces Sale of Common Stock in Its At-the-Market Public Offering investment picks
2013/5/7
BURLINGTON, Mass., May 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Thomas F.
Sign-up for Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease investment picks
2013/5/8
BURLINGTON, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the first quarter ended March 31, 2013.
Sign-up for Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2013 investment picks
2013/3/14
BURLINGTON, Mass., March 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2012.
Sign-up for Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012 investment picks
2013/4/3
BURLINGTON, Mass., April 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, will be hosting an analyst event on Tuesday, April 9, 2013, at 8:00 AM EDT in New York City.
Sign-up for Coronado Biosciences to Host Analyst Event in New York City investment picks
2013/2/19
BURLINGTON, Mass., Feb.
Sign-up for Coronado Biosciences to Participate in Panel Discussion at the Citi 2013 Global Healthcare Conference investment picks
2013/5/6
BURLINGTON, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr.
Sign-up for Coronado Biosciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference investment picks
2013/2/27
BURLINGTON, Mass., Feb.
Sign-up for Coronado Biosciences to Present at the Cowen and Co. 33rd Annual Health Care Conference investment picks
2013/2/7
BURLINGTON, Mass., Feb.
Sign-up for Coronado Biosciences to Present at the Leerink Swann 2013 Global Healthcare Conference investment picks
2013/3/11
BURLINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr.
Sign-up for Coronado Biosciences to Present at the ROTH 25th Annual Growth Stock Conference investment picks
2013/5/1
BURLINGTON, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it will report its financial results for the first quarter 2013, on Wednesday, May 8, 2013 at 8:30 AM ET.
Sign-up for Coronado Biosciences to Report First Quarter 2013 Financial Results investment picks
2013/3/7
BURLINGTON, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it will report its financial results for the fourth quarter and full year 2012, on Thursday, March 14, 2013 at 8:30 AM ET.
Sign-up for Coronado Biosciences to Report Fourth Quarter and Full Year 2012 Results investment picks
2013/2/20
http://media.marketwire.com/attachments/201302/TN-57391_CorpBanca.jpg As of February 19, 2013, CorpBanca's capital totaled 340,358,194,234 common shares, and its shareholder structure is displayed above.
Sign-up for CorpBanca Raises More Than US$620 Million in New Capital investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder to CorpBanca Raises More Than US$620 Million in New Capital
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity